257 related articles for article (PubMed ID: 15136595)
1. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer.
Ayers M; Symmans WF; Stec J; Damokosh AI; Clark E; Hess K; Lecocke M; Metivier J; Booser D; Ibrahim N; Valero V; Royce M; Arun B; Whitman G; Ross J; Sneige N; Hortobagyi GN; Pusztai L
J Clin Oncol; 2004 Jun; 22(12):2284-93. PubMed ID: 15136595
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer.
Tabchy A; Valero V; Vidaurre T; Lluch A; Gomez H; Martin M; Qi Y; Barajas-Figueroa LJ; Souchon E; Coutant C; Doimi FD; Ibrahim NK; Gong Y; Hortobagyi GN; Hess KR; Symmans WF; Pusztai L
Clin Cancer Res; 2010 Nov; 16(21):5351-61. PubMed ID: 20829329
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.
Hess KR; Anderson K; Symmans WF; Valero V; Ibrahim N; Mejia JA; Booser D; Theriault RL; Buzdar AU; Dempsey PJ; Rouzier R; Sneige N; Ross JS; Vidaurre T; Gómez HL; Hortobagyi GN; Pusztai L
J Clin Oncol; 2006 Sep; 24(26):4236-44. PubMed ID: 16896004
[TBL] [Abstract][Full Text] [Related]
4. Prediction of pathologic complete response to sequential paclitaxel and 5-fluorouracil/epirubicin/cyclophosphamide therapy using a 70-gene classifier for breast cancers.
Naoi Y; Kishi K; Tanei T; Tsunashima R; Tominaga N; Baba Y; Kim SJ; Taguchi T; Tamaki Y; Noguchi S
Cancer; 2011 Aug; 117(16):3682-90. PubMed ID: 21305539
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.
Symmans WF; Wei C; Gould R; Yu X; Zhang Y; Liu M; Walls A; Bousamra A; Ramineni M; Sinn B; Hunt K; Buchholz TA; Valero V; Buzdar AU; Yang W; Brewster AM; Moulder S; Pusztai L; Hatzis C; Hortobagyi GN
J Clin Oncol; 2017 Apr; 35(10):1049-1060. PubMed ID: 28135148
[TBL] [Abstract][Full Text] [Related]
6. Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma.
Zhang F; Yang Y; Smith T; Kau SW; McConathy JM; Esteva FJ; Kuerer HM; Symmans WF; Buzdar AU; Hortobagyi GN; Pusztai L
Cancer; 2003 Apr; 97(7):1758-65. PubMed ID: 12655533
[TBL] [Abstract][Full Text] [Related]
7. Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer.
Lee JK; Coutant C; Kim YC; Qi Y; Theodorescu D; Symmans WF; Baggerly K; Rouzier R; Pusztai L
Clin Cancer Res; 2010 Jan; 16(2):711-8. PubMed ID: 20068086
[TBL] [Abstract][Full Text] [Related]
8. Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients.
Park S; Shimizu C; Shimoyama T; Takeda M; Ando M; Kohno T; Katsumata N; Kang YK; Nishio K; Fujiwara Y
Breast Cancer Res Treat; 2006 Sep; 99(1):9-17. PubMed ID: 16752223
[TBL] [Abstract][Full Text] [Related]
9. Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers.
Mazouni C; Kau SW; Frye D; Andre F; Kuerer HM; Buchholz TA; Symmans WF; Anderson K; Hess KR; Gonzalez-Angulo AM; Hortobagyi GN; Buzdar AU; Pusztai L
Ann Oncol; 2007 May; 18(5):874-80. PubMed ID: 17293601
[TBL] [Abstract][Full Text] [Related]
10. Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group.
Martin M; Villar A; Sole-Calvo A; Gonzalez R; Massuti B; Lizon J; Camps C; Carrato A; Casado A; Candel MT; Albanell J; Aranda J; Munarriz B; Campbell J; Diaz-Rubio E;
Ann Oncol; 2003 Jun; 14(6):833-42. PubMed ID: 12796019
[TBL] [Abstract][Full Text] [Related]
11. Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience.
Singh JC; Mamtani A; Barrio A; Morrow M; Sugarman S; Jones LW; Yu AF; Argolo D; Smyth LM; Modi S; Schweber S; Boafo C; Patil S; Norton L; Baselga J; Hudis CA; Dang C
Oncologist; 2017 Feb; 22(2):139-143. PubMed ID: 28167568
[TBL] [Abstract][Full Text] [Related]
12. Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response.
Rajan R; Poniecka A; Smith TL; Yang Y; Frye D; Pusztai L; Fiterman DJ; Gal-Gombos E; Whitman G; Rouzier R; Green M; Kuerer H; Buzdar AU; Hortobagyi GN; Symmans WF
Cancer; 2004 Apr; 100(7):1365-73. PubMed ID: 15042669
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of paclitaxel and carboplatin versus combination chemotherapy with fluorouracil, doxorubicin and cyclophosphamide as a neoadjuvant therapy in patients with inoperable breast cancer.
Akhtar MS; Kousar F; Masood M; Fatimi S; Kokab
J Coll Physicians Surg Pak; 2010 Nov; 20(11):748-52. PubMed ID: 21078249
[TBL] [Abstract][Full Text] [Related]
14. Clinical utility of ABCB1 and ABCG2 genotyping for assessing the clinical and pathological response to FAC therapy in Mexican breast cancer patients.
Turiján-Espinoza E; Ruíz-Rodríguez VM; Uresti-Rivera EE; Martínez-Leija E; Zermeño-Nava JJ; Guel-Pañola A; Romano-Moreno S; Vargas-Morales JM; Portales-Pérez DP
Cancer Chemother Pharmacol; 2021 Jun; 87(6):843-853. PubMed ID: 33740100
[TBL] [Abstract][Full Text] [Related]
15. Feasibility Study of Weekly Nanoparticle Albumin-Bound Paclitaxel (150 mg/m
Kojima Y; Kawamoto H; Nishikawa T; Hayami R; Shimo A; Haku E; Akiyama K; Tsugawa K
Clin Breast Cancer; 2018 Oct; 18(5):374-379. PubMed ID: 29452759
[TBL] [Abstract][Full Text] [Related]
16. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.
Andre F; Mazouni C; Liedtke C; Kau SW; Frye D; Green M; Gonzalez-Angulo AM; Symmans WF; Hortobagyi GN; Pusztai L
Breast Cancer Res Treat; 2008 Mar; 108(2):183-90. PubMed ID: 17468948
[TBL] [Abstract][Full Text] [Related]
17. Genomic grade index is associated with response to chemotherapy in patients with breast cancer.
Liedtke C; Hatzis C; Symmans WF; Desmedt C; Haibe-Kains B; Valero V; Kuerer H; Hortobagyi GN; Piccart-Gebhart M; Sotiriou C; Pusztai L
J Clin Oncol; 2009 Jul; 27(19):3185-91. PubMed ID: 19364972
[TBL] [Abstract][Full Text] [Related]
18. Biomarker analysis of neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or Paclitaxel in early-stage breast cancer.
Horak CE; Pusztai L; Xing G; Trifan OC; Saura C; Tseng LM; Chan S; Welcher R; Liu D
Clin Cancer Res; 2013 Mar; 19(6):1587-95. PubMed ID: 23340299
[TBL] [Abstract][Full Text] [Related]
19. SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer.
Nahleh ZA; Barlow WE; Hayes DF; Schott AF; Gralow JR; Sikov WM; Perez EA; Chennuru S; Mirshahidi HR; Corso SW; Lew DL; Pusztai L; Livingston RB; Hortobagyi GN
Breast Cancer Res Treat; 2016 Aug; 158(3):485-95. PubMed ID: 27393622
[TBL] [Abstract][Full Text] [Related]
20. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer.
Buzdar AU; Singletary SE; Theriault RL; Booser DJ; Valero V; Ibrahim N; Smith TL; Asmar L; Frye D; Manuel N; Kau SW; McNeese M; Strom E; Hunt K; Ames F; Hortobagyi GN
J Clin Oncol; 1999 Nov; 17(11):3412-7. PubMed ID: 10550135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
